Dataset of a Retrospective Multicenter Cohort Study on Characteristics of Immune Checkpoint Inhibitor-induced Encephalitis and Comparison with HSV-1 and Anti-LGI1 Encephalitis

Published: 25 August 2022| Version 4 | DOI: 10.17632/vfpxcbk5bx.4
Leonie Müller-Jensen, Sarah Zierold, Judith Versluis, Wolfgang Boehmerle, Petra Huehnchen, Matthias Endres, Raphael Mohr, Annette Compter, Christian U Blank, Tim Hagenacker, Friedegund Meier, L R, Anja Gesierich, Martin Salzmann, Jessica Hassel, Selma Ugurel, Lisa Zimmer, Patricia Banks, Lavinia Spain, Jennifer A Soon, Tomohiro Enokida, Makoto Tahara, Katharina C Kähler, Ruth Seggewiss-Bernhardt, Catriona Harvey, Georgina V Long, Florian Schöberl, Louisa von Baumgarten, Thomas Hundsberger, Max Schlaak, Lars French, Samuel Knauss, Lucie Heinzerling


Until now, data on clinical features, diagnostic criteria and treatment of irEncephalitis have been limited to case reports and series with small sample sizes. Data to describe clinical differentiators from other types of encephalitis is largely missing. However, patients with extensive malignant disease are also at risk of infectious encephalitis, such as herpes simplex virus (HSV)-1 encephalitis. The objective of this dataset is to provide data on clinical, laboratory, and radiologic features of irencephalitis and allow for comparison with herpes simplex virus (hsv)-1 encephalitis and anti-leucine-rich glioma-inactivated (anti-lgi)-1 encephalitis.



Charite Universitatsmedizin Berlin


Clinical Neurology, Neurotoxicity, Immunotherapy, Clinical Oncology